Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia-Reference-Cited by-同舟云学术

Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia

Published:2003-08 Issue:4 Volume:122 Page:600-606
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Hensel Manfred,Kornacker Martin,Yammeni Sophie,Egerer Gerlinde,Ho Anthony D.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2003.04497.x/fullpdf

Reference22 articles.

1. Infections in patients with chronic lymphocytic leukemia treated with fludarabine;Anaissie;Annals of Internal Medicine,1998

2. Prognostic significance of immune function parameters in patients with chronic lymphocytic leukaemia;Apostolopoulos;European Journal of Haematology,1990

3. Serum immunoglobulins in chronic lymphocytic leukemia;Ben Bassat;American Journal of Medical Science,1979

4. Defective serum gamma globulin formation;Brem;Annals of Internal Medicine,1955

5. Electrophoretic analysis of serum proteins of blood syncrasias;Brown;Journal of Laboratory Clinical Medicine,1948

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first‐line chemoimmunotherapy;Cancer Medicine;2024-08

2. Management of secondary immunodeficiency in hematological malignancies: a Delphi consensus from the Middle East;Frontiers in Hematology;2024-03-08

3. Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis;Annals of Hematology;2024-01-18

4. Immune Dysfunction and Infection – Interaction between CLL and Treatment: A Reflection on Current Treatment Paradigms and Unmet Needs;Acta Haematologica;2023-07-27

5. Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study;Annals of Hematology;2023-06-19